Raising the age to 21 must be complemented by an increase in the state’s tobacco tax, and more resources must be directed to underfunded tobacco prevention programs.
The money is expected to go a long way in funding three events on the city’s calendar: the NBA All-Star Weekend and the NCAA Men’s Basketball Final Four in 2021 and the College Football Playoff National Championship in 2022.
Eli Lilly and Co. said it considered sites in Indianapolis and Pennsylvania but chose North Carolina for quality of life, cost of operations and geographical diversity.
The owners of landscaping firm Heath Outdoor LLC have acquired True North Landscaping LLC, creating an Indianapolis-based company that is expected to have 60 employees and bring in $5 million in revenue this year.
The Indianapolis drugmaker quietly terminated a collaboration with NextCure Inc. after spending $40 million on an up-front fee and equity investment, and with little to show from the partnership.
Under fire over insulin prices, the Indianapolis-based drugmaker said Tuesday morning it is introducing lower-priced versions of its Humalog KwikPen and Humalog Junior KwikPen.
Analysts have said that Dermira’s lead pipeline product, lebrikizumab, has the potential to be the best in class among a wave of similar antibodies to treat eczema.
The fast-growing chain’s concept allows customers to stay in their cars. Also this week: Root & Bone, Gavel, People’s Revel Room, Gymboree Play & Music, Portrait Innovations and more.
The state’s lead economic development agency announced Monday that it secured nearly 300 development deals in 2019 that are expected to result in more than 27,000 new jobs.
So many big stories of 2019—Roger Penske’s purchase of the Indianapolis Motor Speedway, big acquisitions by Eli Lilly and Co. and Elanco, the launch of the Red Line—were as much about the future as they were about the past.
Alimta is Lilly’s third-best-selling drug, with global sales of $2.1 billion last year. The court ruling stops a Canadian competitor from launching a generic version of the drug before its patent expires in 2022.
The year didn’t feature any hostile takeovers or huge disasters. But a lot of companies made big strides in 2019, including Eli Lilly and Co., Corteva and Elanco. And many rejoiced when Washington ended a 2.3% tax on thousands of medical devices.
Podcast host Mason King talks with IBJ Managing Editor Lesley Weidenbener and reporter Anthony Schoettle about Penske Corp.’s acquisition of the Indianapolis Motor Speedway, Eli Lilly and Co.’s biggest acquisition ever, trucking giant Celadon’s demise, Ambrose’s decision to pull back from the GM stamping plant site and more.
The deal, which is expected to close by mid-2020, will swell Elanco from the world’s fourth-largest animal health player to the second-largest, behind only New Jersey-based Zoetis.
